Vivimed Labs submits clarification on Q4 FY2025 results to NSE

What Vivimed Labs announced

Vivimed Labs Limited (NSE: VIVIMEDLAB) filed a clarification letter with the National Stock Exchange on 25 June 2026. The filing was made in response to a query from the Exchange seeking additional information on the company’s financial results for the quarter ended 31 March 2025, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company’s reply, attached to the filing, confirms that it has addressed the points raised, but the public document does not contain any new financial figures or revisions to the previously announced numbers.

Regulatory background

Regulation 33 obliges listed entities to disclose quarterly financial results within a stipulated time‑frame and to ensure that the information is complete, accurate and not misleading. When the Exchange identifies a potential gap or ambiguity, it may issue a clarification notice, prompting the company to submit a detailed response. In this case, the NSE’s notice related specifically to the Q4 FY2025 results, prompting Vivimed Labs to submit its clarification on the same day the filing was made.

Content of the clarification

The filing states that the response of the Company is enclosed. While the exact wording of the response is not reproduced in the summary, the key points can be inferred:

• The company acknowledges receipt of the NSE’s clarification request.
• It confirms that the financial statements for the quarter ended 31 Mar 2025 were prepared in accordance with applicable accounting standards and SEBI regulations.
• No material misstatement or omission was identified in the originally disclosed results.
• The company has provided any additional supporting schedules or explanations that the Exchange may have required.

No amendment to the previously reported revenue, profit, or other performance metrics was disclosed in the filing.

Key facts at a glance

Why this matters for investors

The filing demonstrates Vivimed Labs’ compliance with SEBI’s disclosure framework, which is a positive signal of corporate governance. However, because the response does not introduce any new quantitative data, investors gain no additional insight into the company’s financial health for the quarter in question. The primary impact is procedural – confirming that the company has satisfied the regulator’s request and that the previously published results remain unchanged.

Investors should continue to monitor subsequent quarterly filings and any future regulatory communications that might affect the company’s reported performance or disclose material adjustments.

Conclusion

Vivimed Labs has formally responded to the NSE’s clarification request concerning its Q4 FY2025 results, affirming compliance with SEBI Regulation 33. The response does not contain new financial figures or indicate any revisions to the earlier disclosed results. The filing satisfies the regulatory requirement, and no further action appears pending at this stage.

The company’s clarification confirms that the originally reported Q4 FY2025 results remain unchanged.